Upregulation of lipogenesis is a hallmark of cancer and blocking the lipogenic pathway is known to cause tumor cell death by apoptosis. However, the exact role of lipogenesis in tumor initiation is as yet poorly understood. We examined the expression profile of key lipogenic genes in clinical samples of ductal carcinoma in situ (DCIS) of breast cancer and found that these genes were significantly upregulated in DCIS. We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24 À CD44 þ ESA þ ) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population. Furthermore, the CSCs showed significantly higher level of expression of all lipogenic genes than the counterpart population from non-tumorigenic breast cancer cell line, MCF10A. Importantly, ectopic expression of SREBP1, the master regulator of lipogenic genes, in MCF10A significantly enhanced lipogenesis in stem-like cells and promoted cell growth as well as mammosphere formation. Moreover, SREBP1 expression significantly increased the ability of cell survival of CSCs from MCF10AT, another cell line that is capable of generating DCIS, in mouse and in cell culture. These results indicate that upregulation of lipogenesis is a pre-requisite for DCIS formation by endowing the ability of cell survival. We have also shown that resveratrol was capable of blocking the lipogenic gene expression in CSCs and significantly suppressed their ability to generate DCIS in animals, which provides us with a strong rationale to use this agent for chemoprevention against DCIS.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is the most common type of noninvasive form of breast cancer, which represents an intermediate step between normal breast tissue and invasive breast cancer, and therefore, DCIS is believed to be a precursor of invasive breast cancer. Accordingly, prevention of DCIS is considered to be the most effective way to reduce the breast cancer mortality. However, the molecular mechanism by which normal ductal epithelial cells transform into DCIS is as yet poorly understood. [1] [2] [3] Upregulation of lipogenic genes and overall lipogenesis are hallmarks of cancer and overexpression of these genes are also observed at an early stage of breast tumor; however, the exact role of increased lipogenesis as a cause, consequence or facilitator in DCIS formation is virtually unknown. 4 Inappropriate activation of growth factor signaling including phosphatidylinositol 3 0 -kinase and mitogen-activated protein kinase pathways upregulate the master regulator of lipogenesis, sterol regulatory element-binding protein-1 (SREBP1), which in turn directly activates the transcription of major lipogenic genes including ATP-citrate lyase (ACLY), acetyl CoA carboxylase 1 (ACC1) and fatty acid synthase (FAS). [5] [6] [7] Most of the studies to determine the relationship between do novo lipogenesis and cancers have been undertaken in the late stages of cancer but it is becoming clear that lipogenic enzymes are also activated early in cancer development. For instance, it was reported that overexpression of FAS and ACC1 appear to occur very early in breast cancer progression whereas it is more pronounced in aggressive cancers, which suggests a potential link between increased expression of lipogenic enzymes and increased risk of development of breast cancer. 8 Interestingly, inhibition of lipogenic enzymes blocks cell proliferation, induces apoptosis of cancer cells and retards the growth of human tumors in mouse xenograft models in vivo. [9] [10] [11] [12] [13] These findings suggest that the role of lipogenesis in cancers may extend beyond bulk membrane biosynthesis to meet the demand of rapid cell proliferation. According to the recent cancer stem cell theory, which still remains a hypothesis, tumors develop from a small population of cancer stem-like cells (CSCs) that have a strong tumor-initiating ability.
14 However, it is still unclear whether DCIS also arises from CSCs, and if so, how CSCs contribute to the progression of DCIS. If CSCs are indeed responsible for initiating DCIS, it is of paramount interest to clarify the role of overexpressed lipogenic genes in these cells, which may lead to identification of specific chemopreventive target for DCIS. In this report, we examined the role of SREBP1 and lipogenic genes in CSCs from DCIS cells. Our results suggest that upregulation of lipogenesis endows CSCs with the survival advantage, which is considered as a pre-requisite for DCIS formation. We also found that resveratrol effectively blocks lipogenesis and hence suppresses the incidence of DCIS in our animal model of human DCIS. . The degree of staining in DCIS and normal tissue for each gene was semi-quantified, and the w 2 test was performed to evaluate the level of significance. (c) MCF10A, MCF10AT and DCIS.com cells were cultured in 96-well plate for 48 h and intracellular lipid content was quantified by using the AdipoRed assay. (d) MCF10A, MCF10AT and DCIS.com cells were cultured in triplicates in a 24-well plate for 48 h. Cells were then collected and RNA was extracted. qRT-PCR analysis was then performed to quantify the expression level of ACLY, ACC1 and FAS mRNAs. b-Actin gene was used as an internal control. (e) MCF10A, MCF10AT and DCIS.com cells were cultured and cell lysates were subjected to western blot analysis using antibodies for ACLY, ACC1 and FAS. b-Tubulin was used as loading control. All the experiments were performed in triplicate by taking the values as means±s.d. *Po0.05, **Po0.01 and ***Po0.001. NS, nonsignificant. Figure 2 . Lipogenic genes are regulated by SREBP1 in DCIS. (a) Sections of DCIS clinical specimens were subjected to IHC using antibodies for SREBP1. Representative photo for normal and DCIS are shown (upper panels). The degree of staining for SREBP1 in normal and DCIS was semiquantified, and the w 2 test was preformed to evaluate the level of significance. (b) MCF10A, MCF10AT and DCIS.com cells were cultured and RNA was extracted followed by qRT-PCR analysis to determine the levels of SREBP1 mRNA (upper panel) and cell lysates were used for Western blotting to detect the expression of SREBP1 (lower panel). (c) Knockdown of SREBP1 in DCIS.com cells was performed by infecting with lentiviral carrying shSREBP1 or scrambled shRNA control (shScramble). After cells were cultured, qRT-PCR and western blot analyses were conducted to assess the expression of SREBP1 mRNA levels (upper panel) and protein levels (lower panel). (d) MCF10A and DCIS.com cells were seeded in the 96-well plate (5000 cells/100 ml of medium) and incubated for 24 h. Cells were then infected with lentiviruses expressing shScramble (control) or shSREBP1 (test), and they were further incubated for 72 h followed by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay to measure the cell viability. (e) The expression of various lipogenic genes (ACLY, ACC1 and FAS) in DCIS.com cells with or without knockdown of SREBP1 was examined by qRT-PCR. b-Actin gene was used as an internal control. (f ) DCIS.com cells were seeded in a 24-well plate and incubated for 24 h. They were then infected with lentivirus expressing either shSREBP or shScramble. Media was changed after 8 h and cells were further incubated for 24 h. They were then co-transfected with fulllength wild-type (WT) FAS promoter construct (1431 bp) as well as with Renilla luciferase vector, which is used as an internal control and they were further incubated for 48 h. Cells were then harvested and lysates were analyzed for FAS promoter activity using the dual-luciferase assay systems. (g) Two promoter reporter plasmids carrying either the full-length FAS promoter (1431 bp) containing two SREBP1-binding sites or 115 bp FAS promoter with only one SREBP1-binding site were constructed and transfected into MCF10A and DCIS.com cells. The Renilla luciferase-expressing vector was used as an internal control. The cells were grown for 48 h and dual luciferase assay was performed to measure the FAS promoter activity. (h) DCIS.com cells were transfected with luciferase reporter plasmid with 195 bases of FAS promoter (WT), which has two SREBP1-binding sites or other constructs with following mutations: SREBP1-binding site deleted from À 65 to À 72 bp (referred to as 72-Mut) in 195-bp FAS promoter, SREBP1-binding site deleted from À 145 to À 148 bp (referred to as 148-Mut) in 195-bp FAS promoter or both SREBP1-binding sites were deleted (referred to as 72/148-Mut). Cells were also co-transfected with Renilla luciferase vector, which is used as an internal control, and they were further incubated for 48 h. Cells were then collected and cell lysates were assayed for luciferase activities using the Dual-luciferase reporter assay system. The luciferase activity of each sample was normalized to the Renilla luciferase activity. All the experiments were performed in triplicate. The values are indicated as means ± s.d. *Po0.05, **Po0.01 and ***Po0.001. NS, nonsignificant.
including ACLY, ACC1 and FAS in DCIS by analyzing the existing clinical cohort data (GSE7882) containing 111 DCIS patients. As shown in Figure 1a , we found that all these genes were significantly upregulated in DCIS at all levels of grade (grade I, II and III), whereas very low expression was seen in the adjacent normal breast tissues. To confirm these findings, we did immunohistochemical analysis for these lipogenic genes in a set of human DCIS tissue specimens and found that the proteins of these genes were indeed significantly overexpressed in early stage of breast cancer, whereas the expression of these genes was almost undetectable in normal tissues (Figure 1b) . These results suggest that the lipogenic genes are highly upregulated at an early stage of breast cancer in a coordinated manner and they are likely to have roles in DCIS formation. To further validate our notion and establish a model system in vitro, we utilized three syngenic cell lines. The first one is MCF10A, which is spontaneously immortalized but a non-tumorigenic breast epithelial cell line and is widely used as a model for 'normal' breast epithelial cells. The second cell line is MCF10AT, which was generated after mutated T24 H-ras oncogene transfection to MCF10A cells. This cell line generates DCIS in mice after 6 months followed by progression into more aggressive and invasive tumors. The third cell line, MCF10DCIS.com is derived from the in vivo selection of MCF10AT and induces predominantly comedo-type DCIS in immunodeficient mice when inoculated into its mammary fat pad. [15] [16] [17] When we examined the lipid content in these cell lines, we found that DCIS.com cells had significantly higher amount of total intracellular lipids than MCF10A and MCF10AT (Figure 1c) . We also observed that the major lipogenic genes, ACLY, ACC1 and FAS, were all significantly upregulated in DCIS.com cells compared with MCF10A and MCF10AT when they were examined by quantitative real-time (Figures 1d and e) . Therefore, these results further support our notion that lipogenesis has a critical role in early breast carcinogenesis and that this set of cell line recapitulates the status of lipogenesis in early stage of breast cancer.
Lipogenic genes are regulated by SREBP1 in DCIS SREBP1 is considered as a master regulator for the expression of various lipogenic genes. The nuclear form of SREBP1 binds to the sterol response element (SRE) present in the promoter of major lipogenic genes thereby inducing their transcription. [18] [19] [20] [21] [22] To clarify the role of this gene at an early stage of breast cancer, we have examined the expression of SREBP1 by immunohistochemistry (IHC) in DCIS clinical specimens. As shown in Figure 2a , we found that SREBP1 was indeed significantly overexpressed in DCIS compared with normal gland. These results were confirmed by detecting and quantifying the expression of SREBP1 in MCF10A, MCF10AT and DCIS.com cell lines by western blot and qRT-PCR. As shown in Figure 2b , SREBP1 was indeed significantly upregulated in DCIS.com cells in both mRNA (upper panel) and protein levels (lower panel). These data are consistent with our finding that lipogenic genes that are downstream to SREBP1 were significantly upregulated in DCIS as shown in Figure 1 . To further validate this notion, we silenced the SREBP1 expression in DCIS.com cells by infecting it with lentiviruses expressing short hairpin RNA (shRNA) specific to SREBP1. We first confirmed the stable knockdown of SREBP1 by shRNAs, as shown in Figure 2c (both upper and lower panel). We then examined the effect of shRNAs on cell survival and found that the cell viability was significantly decreased when SREBP1 was knocked down in DCIS.com cells, whereas no such effect was observed in MCF10A cells ( Figure 2d ). This result indicates that SREBP1 is essential for the survival of DCIS cells. We further investigated the effects of silencing SREBP1 on the expression of lipogenic genes, ACLY, ACC1 and FAS and found that they are all significantly suppressed by shSREBP1 (Figure 2e ). To further corroborate these findings, we performed a reporter assay to measure the promoter activity of FAS after infecting shSREBP1 lentivirus to DCIS.com cells. We found that the reporter activity of the FAS gene was significantly decreased by shSREBP1 in comparison with control cells that were only infected with shScramble lentiviruses (Figure 2f ). We also found that the FAS promoter activity was also significantly upregulated in DCIS.com cells compared with MCF10A ( Figure 2g ). Our analysis of the promoter sequence of FAS gene revealed two potential SREBP1-binding sites. When we deleted one of the binding sites in the reporter plasmid (clone 115), the reporter activity was significantly reduced in DCIS.com, whereas such deletion did not affect the activity in MCF10A (Figure 2g ). We also introduced site-specific mutations in the SREBP1-binding sites by deleting 4 bases from À 145 to À 148 bp (referred to as 148-Mut) or from À 65 to À 72 bp (referred to as 72-Mut).
In the third clone, we included both mutations, referred to as 72/148-Mut. Our results of the reporter assay, as shown in Figure 2h , indicate that the FAS promoter activity indeed significantly decreased when these SREBP1-binding sites were mutated individually or both together, suggesting that SREBP1 has a key role in lipogenesis by controlling downstream lipogenic genes in DCIS.
Lipogenic genes are upregulated in CSCs isolated from DCIS.com cells According to the recent cancer stem cell theory, which still remains a hypothesis, a tumor arises from stem cells that have the ability of self-renewal and differentiation and also exhibit resistance to chemotherapy. Therefore, cancer stem cells are considered to be a critical target for chemoprevention and chemotherapy. To determine the DCIS forming potential of CSCs, we isolated tumor-initiating cells or CSCs from DCIS.com using the established cell surface markers for CSCs (CD24 À CD44 þ ESA þ ) by the magnetic-activated cell sorting system (Figure 3a) . Based on the overall yield, the CSCs population was calculated as 1-3% and the purity of CSCs was also confirmed by fluorescence-activated cell sorting analysis (data not shown). To test the tumor-initiating ability of these cells, we performed a limiting dilution analysis by implanting the DCIS.com parental cells and the isolated CSCs of DCIS.com into the mammary fat pad of nude mice. As shown in Figure 3b (upper panel), we found that CSCs of DCIS.com had significantly stronger ability of tumor initiation compared with the parental cells after 4 weeks of injection. The results of our histological examination at the endpoint revealed that the majority of lesions were DCIS with some atypical tumors (Figure 3b , lower panel). These data provide us with a strong rationale to use this specific subset of cell population for further experiments to determine the role of lipogenesis in DCIS formation. We then examined the total lipid content in the CSCs and found that CSCs of DCIS.com had significantly increased amount of lipid than their normal counterparts (Figure 3c ). In order to confirm that this increased lipogenesis is indeed caused by the overexpression of SREBP1 and consequently by its downstream lipogenic enzymes, we performed microarray analysis and found that SREBP1 and other major lipogenic enzymes were indeed overexpressed in CSCs of DCIS.com ( Figure 3d ). These results were also confirmed by qRT-PCR and western blot analysis as shown in Figures 3e and f. We also compared the level of expression of lipogenic genes (SREBP1, ACLY, ACC1 and FAS) in parental cells and stem-like cells population in MCF10A; however, we did not find any significant difference between these cell populations. On the contrary, the expressions of these genes are significantly upregulated in CSCs of DCIS.com compared with that of parental cells. We further confirmed these results by comparing the level of lipid contents in parental cell and CSCs in both MCF10A and DCIS.com and found that lipid synthesis is indeed significantly upregulated in CSC of DCIS but not in MCF10A (Supplementary Figure S1) . Therefore, our data clearly indicate that lipogenesis is highly augmented in CSCs of DCIS through upregulation of SREBP1 and its downstream genes of lipogenesis.
Upregulation of lipogenic genes increases cell viability and proliferation in MCF10A stem-like cells How lipogenesis affects the growth of CSCs is an intriguing question. To address this issue, we infected lentivirus carrying the SREBP1 gene into MCF10A cells and established a cell line ectopically expressing SREEBP1. We then isolated stem-like cells from MCF10A with or without SREBP1 as well as CSCs from DCIS.com. The expression of SREBP1 and down-stream lipogenic genes (ACLY, ACC1 and FAS) in the isolated CSCs was confirmed by qRT-PCR and western blotting (Figures 4a and b) . They were also grown in a low-binding plate and assayed for lipid contents. We found that CSCs of DCIS.com had a significantly higher rate of lipogenesis and growth compared with that from MCF10A; however, ectopic expression of SREBP1 in MCF10A stem-like cells significantly upregulated the lipogenesis and growth (Figures 4c  and d) . Furthermore, when we examined the ability of mammosphere formation, a hallmark of stem-like cells in vitro, we found that CSCs of DCIS.com generated significantly higher number of mammospheres compared with that of MCF10A (Figure 4e) . Interestingly, the ectopic expression of SREBP1 significantly augmented the ability of stem-like cells to generate mammospheres in MCF10A. These results strongly suggest that lipogenesis has an active role in conferring transforming properties by promoting growth and self-renewal of stem-like cells from MCF10A. To further determine the role of lipogenesis in inducing DCIS in an animal model, we isolated stem-like cells from MCF10A and MCF10AT that carry SREBP1 expression vector or empty vector and transplanted them into mammary fat pad of nude mice followed by monitoring the tumor growth. As shown in Figure 4f (left panel), we found that, contrary to our expectation, the signals of MCF10A almost completely disappeared after day 56 regardless of the expression of SREBP1. When MCF10AT was transplanted, the signal was also lost after day 56. Strikingly, however, MCF10AT cells expressing SREBP1 maintained or even increased the signals although the growth of tumor was not visually detectable (Figure 4f, right panel) . These results strongly suggest that SREBP1 does not have oncogenic ability alone; however, it can support cell survival in MCF10AT in vivo. To further test this possibility, we examined the effect of SREBP1 overexpression on survival ability of MCF10AT cells by growing them in serum-free media as well as by treating the cells with 5-fluorouracil, an anticancer drug. As shown in Figures 4g and h, we found that MCF10AT cells carrying SREBP1 were indeed significantly resistant to serum starvation and also to the cytotoxic effects of the chemotherapeutic agent. Resveratol decreases cell viability by inhibiting lipogenesis and inducing apoptosis in CSCs isolated from DCIS.com cells We have previously reported that resveratrol, a natural polyphenolic compound, significantly suppressed tumor growth of breast cancer cells by downregulating FAS and lipogenesis. As lipogenesis has a critical role in self-renewal and proliferation of CSCs of DCIS thus conferring DCIS-initiating ability as described above, we examined a possibility that resveratrol can block DCIS and prevent breast cancer at an early stage. We first isolated CSCs from DCIS.com cells and then examined the effect of resveratrol on the cell proliferation by treating the cells with 50 and 100 mM of resveratrol for 48 h. As shown in Figure 5a , we found that resveratrol significantly decreased cell proliferation in CSCs of DCIS.com in a dose-dependent manner and this decrease in cell survival was found to be a consequence of apoptosis induced by resveratrol (Figure 5b ). We also observed that lipid content was significantly reduced in the cells treated with resveratrol in contrast to the control cells, which were treated with vehicle only (Figure 5c ). These results suggest that downregulation of lipogenesis in CSCs of DCIS is a critical factor for tumor cell death induced by resveratrol. In support of this notion, we found that the expression level of protein and mRNA of SREBP1 and its downstream lipogenic genes were significantly downregulated by resveratrol (Figures 5d and e) . We then examined whether resveratrol is effective in inhibiting mammosphere formation by CSCs of DCIS.com. As shown in 
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Elevated lipogenesis confers cell survival PR Pandey et al Figure 5f , resveratrol indeed significantly decreased the number of mammospheres in CSCs of DCIS.com. Furthermore, we also examined the pro-apoptotic genes, DAPK2 and BNIP3 that we previously identified as downstream targets of apoptosis induced by direct suppression of lipogenesis. 11 As shown in Figure 5g , our data clearly demonstrated that resveratrol treatment of CSCs of DCIS.com resulted in the upregulation of DAPK2 and BNIP3 thus inducing apoptosis. Taken together, these results strongly suggest that resveratrol treatment reduces the lipid content in CSCs of DCIS.com by downregulating SREBP1 and consequently other lipogenic genes, which results in the upregulation of proapoptotic genes DAPK2 and BNIP3 ultimately causing tumor cell death.
Resveratrol treatment prevents DCIS formation in mice As we demonstrated, resveratrol was found to be very effective in curbing the growth and proliferation of CSCs of DCIS.com in culture conditions, and therefore, we tested the efficacy of resveratrol in the prevention of DCIS using a xenograft model. We first administered resveratrol daily for 1 week via oral gavage to female nude mice. We then transplanted CSCs isolated from DCIS.com that were 'labeled' with the luciferase gene and the growth of tumor was monitored by IVIS imaging system. As shown in Figure 6a , DCIS induction was clearly visible within 3 weeks in mice without resveratrol treatment whereas DCIS formation was significantly suppressed in resveratrol treated mice. The average volume of DCIS tumor at the endpoint was significantly reduced in the resveratrol treated mice compared with the control (Figure 6b ). The overall weights of mice were not significantly changed among the control and treated groups during the course of the experiment (data not shown). These results strongly indicate that resveratrol is indeed capable of preventing the formation of DCIS in vivo without any notable side effects. At the endpoint, the mice were killed and sera and DCIS tumors were harvested for further analysis. We found that lipid content in serum was significantly reduced in the mice when they were treated with resveratrol ( Figure 6c ). The results of IHC analysis for the DCIS tumor showed that the expression of SREBP1 and its downstream genes ACLY, ACC1 and FAS were remarkably suppressed in the tumor of the mice treated with resveratrol, whereas the expression of DAPK2 and BNIP3 was strongly augmented in these animals compared with the control group of mice (Figures 6d and e) . These results strongly support the notion that resveratrol decreases the survival and proliferation of CSCs of DCIS growth in mice by inhibiting SREBP1 and other lipogenic genes followed by activating a series of pro-apoptotic genes. Therefore, our results provide a strong rationale to use resveratrol for chemoprevention of DCIS and ultimately to prevent invasive breast cancer. DISCUSSION DCIS is the most common type of noninvasive form of breast cancer, and it represents an intermediate step between normal breast tissue and invasive breast cancer. [1] [2] [3] Therefore, prevention of DCIS is a key step toward reduction of breast cancer death, and elucidating the molecular mechanism of DCIS is of paramount importance in order to define targets for chemoprevention. In this report, we have used syngeneic cell lines, MCF10A, MCF10AT and MCF10DCIS.com, which represent a unique model system for studying normal to DCIS and breast cancer progression. MCF10A is non-tumorigenic and widely used as a 'normal' breast cell. MCF10AT was created by the forced expression of mutated T24 H-ras into MCF10A cells and this cell line generates DCIS after a long latent period (6 months) in mice. DCIS.com is derived from MCF10AT and this cell line develops DCIS in a relatively short time (3-4 weeks) when implanted into animal. [15] [16] [17] We found that there is a distinct cell population (CD24 À CD44 þ ESA þ ) in DCIS.com, which is capable of initiating DCIS formation in vivo, whereas the cells isolated from MCF10A or MCF10AT using the same surface markers did not generate DCIS with the same time period. It should be noted that this cell population from DCIS.com did not become invasive type of cancer at least for up to 4 months. These results strongly suggest that DCIS, like invasive breast cancer, arise from CSCs; however, CSCs are not 'pre-programmed' as suggested before 23 for tumor progression but rather gain the ability of aggressiveness by mutations. Our results also strongly suggest that alteration of Ras signaling and upregulation of lipogenic genes are two critical pre-requisites for CSCs to develop DCIS. In fact, when we knocked down the Ras expression in DCIS.com by shRNAs, we found that the expression of SREBP1 and downstream lipogenic genes, ACLY, ACC1 and FAS were all significantly decreased (Supplementary Figure S2) , indicating that Ras pathway is one of the major regulatory pathways for the upregulation of SREBP1 and lipogenesis.
Elevated level of lipogenic enzymes and upregulation of lipogenesis is a hallmark of cancer and blocking the lipogenic pathway is known to cause tumor cell death by apoptosis. 5, [10] [11] [12] [13] These observations suggest that upregulation of lipogenic genes is not merely a consequence but that it has a critical role in tumor initiation, possibly by providing the source for membrane biosynthesis and metabolic energy through b-oxidation. [24] [25] [26] [27] [28] Our analysis of existing clinical cohort data of DCIS patients and IHC staining of tumor samples clearly indicates that all key lipogenic genes and their master regulator, SREBP1, are significantly Total RNA was extracted from CSCs of DCIS.com that were treated with resveratrol and subjected to qRT-PCR to assess the mRNA levels of SREBP1, ACLY, ACC1 and FAS genes. (f ) CSCs of DCIS.com were seeded in an ultra-low-binding plate in the presence or absence of resveratrol in mammosphere forming medium. The number of mammospheres was counted and images were taken at day 14. (g) CSCs of DCIS.com were treated with or without resveratrol and qRT-PCR analysis was performed to quantify the mRNA expression for the pro-apoptotic genes, DAPK2 and BNIP3. All the experiments were performed in triplicate by taking the values as means ± s.d. *Po0.05, **Po0.01 and ***Po0.001.
However, the stem-like cells of MCF10A with ectopic expression of SREBP1 failed to generate DCIS in animal and transplanted cells became dormant or extinct after 56 days. Strikingly, CSCs of MCF10AT-expressing SREBP1 sustained viability in the animals although it did not significantly support the tumor growth and these CSCs are indeed more resistant to serum starvation and drug treatment than that from MCF10AT alone. It should be noted that MCF10AT was generated by introducing constitutively active mutated T24 H-ras oncogene into MCF10A, 15, 16 and therefore, this marked difference is likely due to the interplay between the Ras signaling and lipogenesis. Ras is known to stimulate cell growth in part by activation of the Raf/extracellular signal-regulated kinase pathway as well as by promoting cell survival through activation of phosphatidylinositol 3 0 -kinase/Akt cascades. [29] [30] [31] Ras was found to be specifically utilizing phosphatidylinositol 3 0 -kinase/Akt pathway to increase cell survival in the presence of apoptotic signals such as those induced by c-Myc. 32 Ras was also shown to promote hMDM2 expression after radiation exposure, which correlates with reduced p53 expression and increased cell survival in HCT116 colon cancer cell lines. 33 On the other hand, overexpression of lipogenic genes is also known to be involved in cell survival. 11, 27, 34 We have indeed previously shown that inhibition of FAS gene in breast cancer causes increase in malonyl-CoA, which leads to upregulation of ceramide and inhibition of CPT-1 and induction of the pro-apoptotic genes BNIP3, TRAIL and DAPK2. 10, 11 However, the fact that neither MCF10A cells expressing SREBP1 nor MCF10AT cells carrying constitutive active form of H-ras did not sustain the cell survival in animals indicates that SREBP1 or H-ras alone is not sufficient to support the survival of CSCs and it requires both functions. It is noteworthy that Ras has also been shown to activate glucose uptake by upregulating the expression of glucose transporters 35 thereby increasing lipogenesis through SREBP1. 36, 37 Although mutations in Ras is relatively rare in breast cancer, aberrant expression of the epidermal growth factor and HER-2/neu receptors are observed in 20-40% of breast cancers, and both of these receptors signal through Ras signaling. [38] [39] [40] Therefore, abnormal expression of Ras signaling and upregulation of lipogenesis at an early stage may synergistically promote cell survival, self-renewal properties of stem-like cells and possibly transition to DCIS phenotype.
CSCs are believed to be responsible for not only tumor initiation but also for chemo-resistance and recurrence. [41] [42] [43] [44] [45] Therefore, targeting CSCs is a rational approach for prevention of DCIS. In this report, we have shown that resveratrol treatment induced tumor cell death in CSCs of DCIS by the activation of pro-apoptotic genes DAPK2 and BNIP3 through downregulation of lipogenic genes. This novel mechanism of resveratrol's action against CSCs of DCIS provides a strong rationale to use this phytochemical for chemoprevention as well as chemotherapy for breast cancer.
MATERIALS AND METHODS
Cell culture and reagents 
Lentivirus production and Infection
Lentivector expression system was purchased from System Biosciences (Mountain View, CA, USA). Packaging and production of green fluorescent protein (control), luciferase and SREBP1-expressing lentiviruses were performed using HEK293TN cells according to the manufacturer's protocol.
Isolation of stem-like cells
Normal epithelial stem-like cells from MCF10A and MCF10A-SREBP1 and CSCs from MCF10AT, MCF10AT-SREBP1 and DCIS.com cells (CSCs of DCIS hereafter) were isolated using the cell surface-specific markers CD24 À
CD44
þ ESA þ by magnetic-activated cell sorting system (Miltenyi Biotec Inc., Auburn, CA, USA) as we described earlier. 11, 46 Cell proliferation assay Ten thousand cells per well were seeded in 96-well plate and cultured for 48 h. For resveratrol experiments, the cells were treated with resveratrol or with vehicle for further 48 h. Same methodology was followed for stem-like cells population after sorting out from the parental cell population; however, ultra-low attachment 96-well plate (Corning Life Sciences, Tewksbury, MA, USA)) was used for culture. Cell proliferation was then measured using CellTiter 96 Aqueous one solution Cell Proliferation Assay kit (Promega Corporation, Madison, WI, USA). The kit solution reagent contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and is widely known as MTS assay. Cell viability was expressed as a percentage relative to untreated cells.
Measurement of lipid content
AdipoRed assay reagent kit (Lonza) was used to measure the intracellular lipid content. In brief, 10 000 cells per well were cultured in 96-well plate. After 48 h, cells were assayed for the quantification of intracellular lipid content according to the manufacturer's instructions.
In situ apoptosis assay CSCs were sorted and cultured in 96-well plate (ultra-low attachment). Cells were treated with different concentrations of resveratrol and further incubated for 48 h. The control wells were treated with vehicle only. The terminal deoxynucleotidyl transferase, dUTP nick-end labeling assay was performed using In situ Cell Death Detection Kit/TMR Red (Roche Diagnostics, Indianapolis, IN, USA). The number of apoptotic cells in each well was counted under a fluorescence microscope and represented in bar diagrams.
Western blotting
Western blotting of the cell lysates was performed as described earlier 11 using antibodies against SREBP1 (1:500, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), ACLY (1:500, Epitomics Inc., Burlingame, CA, USA), ACC1 (1:500, Epitomics Inc.), FAS (1:1000, Immunobiologicals Inc.,Tokyo, Japan), and b-tubulin (1:10000, Upstate Biotechnology, Lake Placid, NY, USA) at 4 1C.
Quantitative real-time PCR
Total RNA was extracted from the cells using RNeasy mini kit (Qiagen, Valencia, CA, USA) and reverse transcribed with Reverse Transcriptase kit (Thermo Scientific, Rockford, IL, USA). PCR was performed in triplicate in DNA engine opticon-2 system (MJ Research Inc., Massachusetts, MA, USA) using Maxima SYBR Green PCR master mix (Thermo Scientific, Rockford, IL, USA). b-Actin was used as an internal control. The following pairs of primers were used for the gene amplification; for SREBP1: 
Dual-luciferase assay
To measure the promoter activity of FAS gene, dual-luciferase assay was performed as described earlier. 22 Briefly, deletion clones were generated by deleting four and eight bases of the two SREBPbinding/E-Box sequences on the FAS gene promoter using the 195 bp FAS promoter-reporter plasmid by Quick Change Site-Directed Mutagenesis kit (Strategene, Wilmington, DE, USA) according to the manufacturer's protocol. These plasmids were transfected into cultured cell lines by using Lipofectamine 2000 (Invitrogen), and they were further incubated for 48 h. Empty luciferase vectors were used as control. Renilla luciferase was co-transfected and used as an internal control for normalization. Cells were harvested and cell lysates were used for the Dual-luciferase assays using a luciferase assay kit (Promega) and Luminometer (Berthold Detection Systems, Pforzheim, Germany).
Gene expression microarray profiling and cohort data analysis Stem-like cells were isolated from MCF10A and DCIS.com cells and total RNA was extracted using the RNeasy mini kit (Qiagen) and re-purified using the RNA cleanup kit (Qiagen). Labeling and hybridization of the samples to Human gene 1.0ST chip (Affymetrix Inc., Santa Clara, CA, USA) was performed by the CFG Microarray Core Facility, New York, USA. Normalization of the chip was performed using RMA algorithm in Expression console software (Affymetrix). These expression data were submitted to the NCBI Gene Expression Omnibus (GEO) under accession number GSE25976. Clustering and its visualization were performed using Cluster and TreeView software. For cohort analysis, we chose DCIS clinical cohort GSE7882 breast cancer microarray data that contain the information of patients with DCIS from GEO database.
IHC analysis
Formalin-fixed paraffin-embedded DCIS tissue specimens were obtained from the pathology archives of Iwate Medical School (Iwate, Japan). IHC Elevated lipogenesis confers cell survival PR Pandey et al staining was performed as described earlier 11, 46 using antibodies against SREBP1, ACLY, ACC1, FAS, DAPK2 (Santacruz) and BNIP3 (Biocarta LLC, San Diego, CA, USA) at 4 1C. For the mouse DCIS tissue specimens, DCIS tumors were harvested from mice at the endpoint.
Mammosphere assay
Stem-like cells were isolated from the parental cells and viability was measured and counted. Single-cell suspensions of stem-like cells (1000 cells per 24-well plate) were plated in phosphorylcholine treated ultra-low attachment plate (NOF Corporation, White Plains, NY, USA) in mammosphere forming medium containing Dulbecco's modified Eagle's medium/F12 supplemented with 2% B27 (Invitrogen), 20 ng/ml epidermal growth factor and 4 mg/ml insulin (Sigma-Aldrich, St Louis, MO, USA). The numbers of mammospheres were counted and images were taken at day 14.
Animal experiments
Limiting dilution analysis. In order to determine the tumorigenic potential of CSCs of DCIS, we performed the limiting dilution analysis. The number of parental and CSCs was counted and 1 Â 10 3 , 1 Â 10 4 and 1 Â 10 5 cells were suspended in media and mixed with equal volume of matrigel (BD Biosciences, San Jose, CA, USA). A total of 100 ml of cell mixture was injected into the fourth mammary gland of female nude mice (3-4 weeks; n ¼ 7). Mice were then observed for a period of 4 weeks and the formation of DCIS was counted in each mice. At the endpoint, DCIS tumors were harvested and tissue sections were made and stained with hematoxylin and eosin.
Chemopreventive effect of resveratrol in in vivo. To determine the chemopreventive effects of resveratrol against DCIS in in vivo, resveratrol suspended in phosphate-buffered saline (22.4 mg/kg body weight) was administered daily to 3-4 weeks old female nude mice via oral route (gavage). The control group received the vehicle only. After a week of resveratrol administration, CSCs of DCIS-expressing luciferase gene (1 Â 10 5 cells) were injected into the fourth mammary gland (both left and right) of mice while continuing the resveratrol treatment for the next 5 weeks. In vivo imaging was performed to monitor the tumor growth using the IVIS Imaging System (Caliper Life Sciences, Hanover, MD, USA) by measuring photon flux after 15 min of intraperitoneal injection of 150 mg/kg of luciferin in every 5 days. Mice were killed at the endpoint and DCIS tumors were harvested and fixed with 20% formalin and sections were also subjected to IHC analysis.
Statistical analysis
All the numerical values were expressed as the mean±s.e. of at least three independent experiments. Statistical significance was determined by Student's t-test or one-way analysis of variance. P-valueso0.05 were considered significant. Statistical procedures were carried out using Graphpad prism (Graphpad Software Inc., San Diego, CA, USA).
